OIS@ASCRS
Richard L. Lindstrom, MD, Founder & Attending Surgeon – Minnesota Eye Consultants Participant: Richard Lindstrom, MD Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized…
Read MoreRhopressa is a Rho-kinase and norepinephrine transporter inhibitor and lowers episcleral venous pressure, with phase 3 efficacy data expected mid-Q2 2015, and an FDA filing…
Read MoreDedicated to solving compliance problems with ophthalmic medications, ForSight VISION5 has developed Helios, a non-invasive, sustained-release drug delivery system that remains in place for 6…
Read MoreParticipants: Kuldev Singh, MD, MPH Dr. Kuldev Singh is Professor of Ophthalmology and Director of the Glaucoma Service at the Stanford University School of Medicine.…
Read MoreParticipant: Richard Lindstrom, MD Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. View Full Profile
Read MoreParticipants: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare…
Read More“It’s becoming more like cage fighting than company building.” The Drug Delivery market is increasingly competitive. CEOs from the sector’s leading innovators Ocular Therapeutix, Kala…
Read MoreThe company is evaluating sustained-release injectable anti-VEGF drug depots along with using its proprietary hydrogel platform technology for anterior segment disorders (specifically pain and inflammation).…
Read MoreThe company’s proprietary Verisome drug delivery technology is being used as the base for IBI-10090, for post-cataract surgery inflammation. The dexamethasone compound completed a pivotal…
Read MoreBy penetrating the mucosal barrier in the eye, Kala’s Mucosal Penetrating Products (MPPs) “enhances pharmacokinetics” and can be used to treat both anterior and posterior…
Read MoreENV515 is a proprietary, fully biodegradable PRINT (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")